^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MV-NIS

    i
    Associations
    News

    Trials

    Company:
    Vyriad
    Drug class:
    Immunostimulant, Cell death stimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer (NCT02068794)
    Phase 1/2
    Mayo Clinic
    Active, not recruiting
    Last update posted :
    06/13/2024
    Initiation :
    03/31/2014
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    CD4
    |
    MV-NIS
    Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT (NCT02962167)
    Phase 1
    Sabine Mueller, MD, PhD
    Completed
    Last update posted :
    03/20/2024
    Initiation :
    02/22/2017
    Primary completion :
    05/10/2023
    Completion :
    05/10/2023
    CD4
    |
    MV-NIS
    Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer (NCT01846091)
    Phase 1
    Mayo Clinic
    Completed
    Last update posted :
    02/14/2023
    Initiation :
    04/09/2013
    Primary completion :
    09/18/2019
    Completion :
    11/26/2019
    HER-2 • ER • PGR
    |
    HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive
    |
    MV-NIS
    Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma (NCT01503177)
    Phase 1
    Mayo Clinic
    Completed
    Last update posted :
    01/11/2021
    Initiation :
    11/01/2011
    Primary completion :
    04/11/2019
    Completion :
    04/11/2019
    CD4
    |
    MV-NIS